Pharmacological characterization of the first in class clinical candidate PF‐05190457: a selective ghrelin receptor competitive antagonist with inverse agonism that increases vagal afferent firing and glucose‐dependent insulin secretionex vivo
Authors:
Open Access
- 19 January 2016
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 173 (9) , 1452-1464
Abstract
Background and Purpose: Ghrelin increases growth hormone secretion, gastric acid secretion, gastric motility and hunger but decreases glucose‐dependent insulin secretion and insulin sensitivity in humans. Antagonizing the ghrelin receptor has potential as a therapeutic approach in the treatment of obesity and type 2 diabetes. Therefore, the aim was to pharmacologically characterize the novel small‐molecule antagonist PF‐05190457 and assess translational pharmacologyex vivo.Experimental Approach: Radioligand binding in filter and scintillation proximity assay formats were used to evaluate affinity, and europium‐labelled GTP to assess functional activity. Rat vagal afferent firing and calcium imaging in dispersed islets were used asnativetissues underlying food intake and insulin secretion respectively.Key Results: PF‐05190457 was a potent and selective inverse agonist on constitutively active ghrelin receptors and acted as a competitive antagonist of ghrelin action, with a humanKdof 3 nM requiring 4 h to achieve equilibrium. Potency of PF‐05190457 was similar across different species. PF‐05190457 increased intracellular calcium within dispersed islets and increased vagal afferent firing in a concentration‐dependent manner with similar potency but was threefold less potent as compared with thein vitro Kiin recombinant overexpressing cells. The effect of PF‐05190457 on rodent islets was comparable with glibenclamide, but glucose‐dependent and additive with the insulin secretagogue glucagon‐like peptide‐1.Conclusions and Implications: Together, these data provide the pharmacologicalin vitroandex vivocharacterization of the first ghrelin receptor inverse agonist, which has advanced into clinical trials to evaluate the therapeutic potential of blocking ghrelin receptors in obesity and type 2 diabetes.Keywords
This publication has 90 references indexed in Scilit:
- Retracted: KATP channels in the nodose ganglia mediate the orexigenic actions of ghrelinThe Journal of Physiology, 2015
- A practical guide for the stabilization of acylghrelin in human blood collectionsClinical Endocrinology, 2011
- Ghrelin and gastric acid secretionWorld Journal of Gastroenterology, 2008
- Small-Molecule Ghrelin Receptor Antagonists Improve Glucose Tolerance, Suppress Appetite, and Promote Weight LossEndocrinology, 2007
- Acute Effects of Ghrelin on Insulin Secretion and Glucose Disposal Rate in Gastrectomized PatientsThe Journal of Clinical Endocrinology & Metabolism, 2006
- Ghrelin receptors in rat and human nodose ganglia: putative role in regulating CB-1 and MCH receptor abundanceAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2006
- Non-Acylated Ghrelin Counteracts the Metabolic But Not the Neuroendocrine Response to Acylated Ghrelin in HumansThe Journal of Clinical Endocrinology & Metabolism, 2004
- Growth hormone secretagogue receptor expression in the cells of the stomach-projected afferent nerve in the rat nodose ganglionNeuroscience Letters, 2003
- Dose-Dependent Inhibition by Ghrelin of Insulin Secretion in the MouseEndocrinology, 2003
- The Tissue Distribution of the mRNA of Ghrelin and Subtypes of Its Receptor, GHS-R, in HumansThe Journal of Clinical Endocrinology & Metabolism, 2002